New York State Teachers Retirement System Makes New $1.22 Million Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

New York State Teachers Retirement System bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,749 shares of the company's stock, valued at approximately $1,217,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. International Assets Investment Management LLC purchased a new position in shares of TransMedics Group in the 2nd quarter worth about $47,000. USA Financial Formulas bought a new stake in shares of TransMedics Group during the 3rd quarter worth $55,000. J.Safra Asset Management Corp boosted its stake in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company's stock worth $67,000 after buying an additional 383 shares in the last quarter. Signaturefd LLC raised its position in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company's stock worth $67,000 after purchasing an additional 93 shares during the period. Finally, Amalgamated Bank increased its holdings in shares of TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company's stock worth $168,000 after buying an additional 70 shares during the period. 99.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on TMDX shares. Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $169.00 to $109.00 and set a "buy" rating for the company in a report on Tuesday, October 29th. Oppenheimer dropped their price target on shares of TransMedics Group from $200.00 to $125.00 and set an "outperform" rating on the stock in a report on Tuesday, October 29th. Morgan Stanley raised their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an "equal weight" rating in a report on Monday, July 15th. Piper Sandler reaffirmed an "overweight" rating and set a $180.00 price target on shares of TransMedics Group in a report on Tuesday, October 29th. Finally, Stephens increased their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, TransMedics Group presently has a consensus rating of "Buy" and an average price target of $144.80.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX traded up $0.48 during midday trading on Friday, hitting $85.98. The company had a trading volume of 1,248,860 shares, compared to its average volume of 2,090,369. The business's 50-day simple moving average is $132.03 and its 200-day simple moving average is $139.54. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The stock has a market cap of $2.89 billion, a price-to-earnings ratio of 91.47 and a beta of 2.08. TransMedics Group, Inc. has a twelve month low of $55.29 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business's revenue for the quarter was up 63.7% on a year-over-year basis. During the same period last year, the company earned ($0.12) EPS. On average, research analysts predict that TransMedics Group, Inc. will post 1.07 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In related news, insider Nicholas Corcoran sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now directly owns 21,105 shares of the company's stock, valued at $3,714,902.10. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Nicholas Corcoran sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now owns 21,105 shares of the company's stock, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares of the company's stock, valued at $9,457,269.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,958 shares of company stock valued at $5,230,528 in the last three months. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.